PMID: 8938817Oct 1, 1996Paper

Reduced intravenous glutathione in the treatment of early Parkinson's disease

Progress in Neuro-psychopharmacology & Biological Psychiatry
G SechiG Rosati

Abstract

1. Several studies have demonstrated a deficiency in reduced glutathione (GSH) in the nigra of patients with Parkinson's Disease (PD). In particular, the magnitude of reduction in GSH seems to parallel the severity of the disease. This finding may indicate a means by which the nigra cells could be therapeutically supported. 2. The authors studied the effects of GSH in nine patients with early, untreated PD. GSH was administered intravenous, 600 mg twice daily, for 30 days, in an open label fashion. Then, the drug was discontinued and a follow-up examination carried-out at 1-month interval for 2-4 months. Thereafter, the patients were treated with carbidopa-levodopa. 3. The clinical disability was assessed by using two different rating scale and the Webster Step-Second Test at baseline and at 1-month interval for 4-6 months. All patients improved significantly after GSH therapy, with a 42% decline in disability. Once GSH was stopped the therapeutic effect lasted for 2-4 months. 4. Our data indicate that in untreated PD patients GSH has symptomatic efficacy and possibly retards the progression of the disease.

Associated Clinical Trials

Dec 24, 2014·Laurie Mischley

References

Jan 1, 1976·Annual Review of Biochemistry·A Meister, S S Tate
Oct 1, 1978·Endocrinology·E M CornfordW H Oldendorf
Dec 1, 1992·Neurology·P JennerC D Marsden
Feb 1, 1992·Neurology·V V MyllyläE H Heinonen
Jul 1, 1986·Annals of Internal Medicine·W M PardridgeH J Frank
Feb 1, 1989·Journal of Neurochemistry·P RiedererM B Youdim
Oct 1, 1969·Archives of Neurology·M D YahrM M Hoehn
Jan 1, 1983·Journal of Neurology·M Tomonaga
Jun 1, 1984·Annals of Neurology·S I Harik, T McGunigal
Dec 13, 1982·Neuroscience Letters·T L PerryS Hansen
Jun 1, 1982·Neurology·P F TeychenneB Vern

❮ Previous
Next ❯

Citations

Jul 13, 2011·The Journal of Membrane Biology·Mustafa NazıroğluAbdulhadi Cihangir Uğuz
Dec 17, 2003·Journal of the Neurological Sciences·Madhavi ThomasElizabeth Protas
Mar 12, 1998·Brain Research. Brain Research Reviews·J S Bains, C A Shaw
Dec 18, 2012·The Journal of Alternative and Complementary Medicine : Research on Paradigm, Practice, and Policy·Laurie K MischleyJohn S Finnell
Aug 24, 2005·Antioxidants & Redox Signaling·G D ZeevalkJ Ehrhart
Mar 12, 2011·Antioxidants & Redox Signaling·Valerio Chiurchiù, Mauro Maccarrone
Dec 4, 2012·Nutrients·William M JohnsonJohn J Mieyal
Jan 7, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Nadella KumudiniVijay Kumar Kutala
Aug 22, 2014·Current Treatment Options in Neurology·Danny BegaTanya Simuni
Apr 9, 2016·Journal of Fluorescence·Qian LiWeiying Lin
Jun 8, 2013·Pharmaceutical Development and Technology·Jingyuan WenRaid Alany
Jul 23, 2015·Molecular Neurobiology·Ewa NiedzielskaMałgorzata Filip
Feb 28, 2015·Environmental Science and Pollution Research International·Zhoura LakrounRachid Soulimani
Nov 15, 2008·Journal of Pharmacological Sciences·Koji AoyamaToshio Nakaki
Jun 1, 2016·Environmental Science and Pollution Research International·Asma LahouelRachid Soulimani
Apr 20, 2006·The Annals of Pharmacotherapy·Cynthia A Weber, Michael E Ernst
May 26, 2017·Antioxidants & Redox Signaling·Carsten Berndt, Christopher Horst Lillig
Jul 20, 2001·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·J K Andersen
Feb 21, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserDavid Perlmutter
Aug 1, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Laurie K MischleyLeanna J Standish
Jul 4, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniela Berg, Helmine Hochstrasser
Mar 13, 2010·Annals of Neurology·Masato AsanumaMiho Murata
Feb 5, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Yutaka NaitoHidekazu Tomimoto
Jun 23, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Heather L Martin, Peter Teismann
Sep 6, 2019·Nutrients·Deanna M Minich, Benjamin I Brown
Aug 28, 2020·Expert Opinion on Investigational Drugs·Margherita FabbriOlivier Rascol
Sep 30, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Gian Pietro Sechi
Sep 12, 2015·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·E A KatuninaG N Avakyan
Dec 16, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Giuseppe TardioloEmanuela Mazzon
Aug 22, 2006·JAAPA : Official Journal of the American Academy of Physician Assistants·Sharon S Moser, Wendy Besler-Panos
Feb 25, 2016·NPJ Parkinson's Disease·Laurie K MischleyJeannie M Padowski

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.